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HSP60 expression during
carcinogenesis: a molecular
‘‘Proteus’’ of carcinogenesis?
Francesco Cappello and Giovanni Zummo
Sir,
I read with much interest the comprehensive review by
Ciocca and Calderwood (2005) in which they analyze the
diagnostic, prognostic, predictive, and treatment values of
a number of Hsps in oncology. Concerning the implica-
tions of Hsps in cancer diagnosis in particular, they re-
port that since ‘‘Hsps are overexpressed in a wide range
of malignant cells and tissues . . . Hsp detection is not
useful in diagnostic immunopathology.’’ Nevertheless,
‘‘Hsp expression levels can help indicate the presence of
abnormal changes during the process of carcinogenesis.’’
The authors support this remark by reference to several
papers by our group (Cappello et al 2002–2003, 2003a,
2003b, 2003c) in which we demonstrate that Hsp60 and
Hsp10 are overexpressed during colorectal, prostatic, and
exocervical carcinogenesis.
We would now like to add some recent information and
a new topic.
Lebret et al (2003) were the first to demonstrate that
Hsp60 could also lose its expression during carcinogen-
esis, specifically in a vesical one. This datum was quite
surprising for us and we decided to perform a study
(submitted) on a wide range of bladder transitional cell
carcinomas (TCC) at different levels and stages. In this
study we show that Hsp60 disappears in TCC in relation
to the tumoral level of the neoplasm. At the same time,
we recorded the overexpression of Hsp10 in the same
tumors. In agreement with our previous studies (Cap-
pello et al 2004), we suggested that Hsp10 may have dif-
ferent roles than that of the cochaperonin in human cells,
ie, contributing to cellular differentiation and prolifera-
tion.
Interestingly, we recently reported that Hsp60 might
also be a novel biomarker during bronchial carcinogenesis
(Cappello et al 2005). Indeed, we studied a series of bron-
chial biopsies of subjects who were smokers, and we
showed that normal and hyperplastic mucosae present
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Hsp60 immunopositivity in 60% of epithelial cells; by
contrast, only 5% of epithelial elements of patients with
squamous metaplasia showed Hsp60 presence on epithe-
lial surface, and its positivity completely disappeared in
dysplastic and tumoral specimens. We still have no data
on Hsp10 presence and expression in bronchial carcino-
genesis.
In our letter, we would like to express an opinion and
pose a question. Even if it is still unrealistic to affirm that
Hsp60 overexpression is correlated with cancer develop-
ment and progression (since it seems to depend on the
tissues of origin of the neoplasm), we ask ‘Why does
Hsp60 show a discrepancy in its expression during car-
cinogenesis?’ For example, since it has been suggested
that Hsp60 may have both pro- and antiapoptotic roles
in tumoral cells (Faried et al 2004; Di Felice et al 2005),
we may postulate that its levels may be dependent on the
expression of other proteins involved in activation of the
apoptotic pathway. We now need to find these proteins.
In conclusion, we believe that a better understanding
of the molecular bases of Hsp60 expression during car-
cinogenesis will probably also expand our therapeutic
targets against cancer.
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